CNS safety failures during GLP toxicology testing are infrequent, placing the burden of failure on the patient.

Brain organoids offer a promising solution by recapitulating key features of the human cortex—cell sourcing, cellular diversity, and 3D structure—enabling researchers to predict neurotoxicity before clinical trials.

In this on-demand webinar, discover how CNS-3D organoids deliver unparalleled consistency, with reproducible viability, morphology, and electrophysiology across plates and lots.

‍

‍

Discussion Points
‍

CNS-3D mirrors composition and maturity of the human cortex (~50% neurons, ~50% astrocytes), with a representative neuronal mix (~90% excitatory, ~10% inhibitory)
‍

Spontaneous electrophysiological activity provides a sensitive, translational readout for neurotoxicity
‍

CNS-3D is 7.4x more predictive of human clinical outcomes than animal models and achieves 93.3% specificity
‍

Uniform size (<1% CV) and standardized biology deliver reproducible results batch-to-batch and year-to-year, enabling routine adoption

‍

‍

Speakers

‍

Andrew LaCroix, PhD
‍

Andrew LaCroix is a Lead Scientist at 28bio specializing in the development of iPSC-derived brain organoid models and their applications to preclinical safety and efficacy testing. Specifically, he has focused on predictive neurotoxicity assays and human-first drug discovery to reduce clinical failure rates and improve patient outcomes.

‍

Elliott Johns
‍

Elliott Johns is the Associate Director of Marketing and Product Management at 28Bio focused on bridging scientific innovation and industry application of new approach methods to improve the prediction of clinical outcomes.